Accelerating SUD Therapy Discovery with AI/ML Driven BBB Permeability Predictions

VeriSIM Life partnered with our client to translate drug candidates targeting SUD patient therapies more rapidly and accurately than traditional methods that depend on the experimental uncertainty of modeling for data. In the first stage of the collaboration, VeriSIM Life’s hybrid AI platform, BIOiSIM, was used to predict pharmacokinetic (PK) properties necessary for the selection of potentially viable drug lead candidates. A PK model was developed to determine brain disposition of the drug molecules.

Download the Report